Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Powles, Thomas; Plimack, Elizabeth R.; Soulieres, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frederic; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J.; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L. Rhoda; Atkins, Michael B.; Rini, Brian, I

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Autor(en):

Powles, Thomas; Plimack, Elizabeth R.; Soulieres, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frederic; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J.; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L. Rhoda; Atkins, Michael B.; Rini, Brian, I

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

Lancet Oncology (2020), Bd. 21, H. 12, S. 1563-1573

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(20)30436-8

ISSN:

1474-5488